+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 25 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the combination of camizestrant and ribociclib in patients with estrogen receptor-positive ER, human epidermal growth factor receptor 2-negative HER2- advanced breast cancer who have not previously received systemic treatment for their advanced disease. This Phase IIIb, global, multicenter, single-arm study aims to assess the effectiveness, safety, and tolerability of this treatment approach. Participants will receive daily oral doses of camizestrant at 75 mg and ribociclib at 600 mg. All enrolled patients will take these medications until they decide to stop treatment or for any other reason that leads to discontinuation. The study does not involve comparison groups but monitors treatment outcomes in all participants receiving the combination. During the study, participants will undergo evaluations to monitor how long they remain on treatment before starting another therapy or experiencing progression. Researchers will assess treatment safety, including any significant side effects occurring within the first six months. Participants will have regular visits to assess their health status and treatment response. The total study duration extends up to two years following the first dose of treatment.

Age: 18Years - 130YearsAll GendersPhase 3
89 locations
S

Actively Recruiting

Researchers are studying circulating tumor cells CTCs and clusters of CTCs in various types of cancer to better understand their biology and role during disease progression. This observational study aims to evaluate CTCs as biomarkers and identify key signaling networks active in these cells, involving patients with different solid tumor cancers. The study is led by the University Hospital in Basel, Switzerland, and covers a wide range of cancer stages and subtypes. Participants will provide blood samples, typically collected in tubes containing EDTA, for isolation and detailed analysis of CTCs. For those undergoing tumor resection, additional samples will be taken from tumor draining vessels. These samples will undergo molecular analysis, culture, and drug screening to explore characteristics of the CTCs. The study does not involve any treatments but focuses on collecting and analyzing these biological samples over time. Participants will be followed for an extended period, up to around 20 years, with evaluations including overall survival and progression-free survival. The total number of isolated CTCs will also be monitored throughout the study. The long-term observation allows researchers to study changes in CTCs over disease progression. Participants will provide informed consent and undergo regular blood sampling, with no interventions beyond sample collection.

Age: 18Years +All Genders
2 locations
C

Actively Recruiting

Researchers are investigating the best approach to treat low-risk patients with isolated subsegmental pulmonary embolism SSPE, a type of blood clot in small lung arteries. The study aims to determine whether monitoring patients without anticoagulation is as safe and effective as giving anticoagulant medication. This is important because many patients currently receive anticoagulants that carry a risk of bleeding, but it is unclear if all patients with isolated SSPE need this treatment. Patients in the trial are randomly assigned to one of two groups. One group receives the anticoagulant drug rivaroxaban, starting with 15 mg twice daily for 21 days, then 20 mg once daily for a total of 90 days. The other group receives a placebo matching the same schedule. The trial compares clinical surveillance without anticoagulation to anticoagulation treatment to assess safety and effectiveness. Participants will be followed for 90 days after randomization to monitor for recurrent venous thromboembolism, significant bleeding events, and overall survival. Researchers will track these outcomes through clinical assessments and safety monitoring. This study is designed to evaluate if careful monitoring alone is a safe alternative to anticoagulation in selected patients with isolated SSPE, potentially reducing bleeding risks from treatment.

Age: 18Years +All GendersPhase 4
40 locations
O

Actively Recruiting

Researchers are studying adult patients with unresectable or metastatic HER2-low and HER2-ultralow expressing breast cancer who have either received prior chemotherapy in the metastatic setting or have hormone receptor-positive disease not suitable for endocrine therapy. The study aims to observe the real-world use and effects of Trastuzumab deruxtecan T-DXd and conventional chemotherapy in these populations. This observational study collects data without administering any study drugs directly, focusing on patient characteristics, treatment patterns, and safety. Participants will be grouped into those receiving T-DXd according to approved medical guidelines and those treated with conventional chemotherapy, including drugs like capecitabine and paclitaxel. The study records treatment details and the management of any adverse reactions, with Group 2 patients contributing baseline data on conventional chemotherapy. Treatments are given as part of routine clinical care, following the Summary of Product Characteristics, without experimental interventions. During the study, participants treatment courses will be tracked for up to approximately 37 months. Researchers will evaluate the time to next treatment, treatment discontinuation, safety events, and patients impressions of treatment tolerability and quality of life. Data collection includes physician reports, patient diaries, and quality of life questionnaires. This long-term monitoring helps to understand treatment patterns and patient experiences in real-world settings.

Age: 18Years +All Genders
216 locations
P

Actively Recruiting

Researchers are evaluating the effectiveness of trastuzumab deruxtecan T-DXd combined with either rilvegostomig or pembrolizumab compared to chemotherapy plus pembrolizumab in treating women with HER2-expressing, mismatch repair proficient, advanced or recurrent endometrial cancer. This Phase III randomized study aims to assess progression-free survival PFS as its primary outcome, with additional measures including overall survival and treatment safety. Participants are assigned to one of three treatment groups Arm A receives T-DXd and rilvegostomig intravenously every three weeks Arm B receives T-DXd and pembrolizumab intravenously every three weeks Arm C receives carboplatin, paclitaxel, and pembrolizumab every three weeks for six cycles followed by pembrolizumab maintenance every six weeks for up to 20 cycles. Treatment continues until disease progression or other discontinuation criteria are met. Docetaxel may replace paclitaxel if necessary due to allergic reactions. During the study, participants will undergo various assessments including imaging to monitor disease progression according to RECIST criteria, safety evaluations, pharmacokinetic and immunogenicity testing, and patient-reported tolerability measures. These assessments occur throughout treatment and up to approximately 70 months for survival and safety follow-up. The study involves regular monitoring by independent review and investigator assessments to evaluate treatment effects and patient outcomes.

Age: 18Years +FEMALEPhase 3
257 locations
E

Actively Recruiting

Researchers are evaluating whether digital voice analysis can identify measurable changes in audio signals that reflect frailty and emotional distress in patients with cancer. Frailty, a common syndrome especially among older adults, increases risks such as falls, disability, hospitalization, and death. Detecting frailty and distress early is important for improving patient care and treatment outcomes. This study will gather voice recordings alongside conventional assessments to explore the potential relationship between voice features and patient wellbeing over time. Participants will use a tablet to describe images freely while their speech is recorded with synchronized audio and video. These recordings will be analyzed for various voice parameters like frequency, voice quality, and fluency. Alongside voice data, participants will complete the G8 questionnaire to assess frailty and the Distress Thermometer to measure psychological distress. The study includes two groups of cancer patients from a palliative care center and a mid-size cancer center, with multiple recording sessions over several weeks. Participants will be followed for up to 16 weeks, during which changes in specific voice features such as fundamental frequency, jitter, shimmer, voice strength, and speech duration will be tracked and compared to clinical assessments. The study aims to conduct detailed analyses of how voice characteristics vary with frailty and distress both between different patients and within the same patient over time. Data collection includes clinical evaluations and questionnaires, with researchers monitoring these changes to identify potential markers for future larger studies.

Age: 18Years +All Genders
2 locations
T

Actively Recruiting

Researchers are observing the long-term outcomes and adherence of the Inspire UAS System, a device used for patients with obstructive sleep apnea OSA. This observational registry aims to track the patients experience with the Inspire System through regular clinical care visits, capturing data throughout the patients use of the device. The study is sponsored by Inspire Medical Systems, Inc. and does not require any additional interventions or testing beyond routine care. Participants in this study will have the Inspire UAS System implanted, which includes three components an implantable pulse generator, a stimulation lead, and a sensing lead. Patients also receive a remote control to activate the therapy. The registry collects data during routine follow-up visits and does not involve experimental treatments or randomization. Throughout the study, participants will have clinical data collected such as the Apnea Hypopnea Index AHI, Epworth Sleepiness Scale ESS, and other sleep-related assessments if available from routine care. Researchers will monitor therapy use, patient experience, and any adverse events reported during implant and follow-up visits. The study will continue through April 2035, allowing long-term observation of the Inspire Systems use in everyday clinical settings.

Age: 18Years +All Genders
21 locations
C

Actively Recruiting

This research aims to determine whether performing an extended pelvic lymph node dissection ePLND during radical prostatectomy benefits men with high-risk prostate cancer. The study investigates if ePLND improves cancer staging and removes undetectable cancer cells that standard imaging techniques like PSMA-PET might miss, potentially leading to better treatment outcomes. The trial is a multicenter, randomized phase III study sponsored by University Hospital, Basel, Switzerland. Participants will be randomly assigned to one of two groups radical prostatectomy with extended pelvic lymph node dissection or radical prostatectomy without the extended lymph node dissection. Extended PLND involves removing more lymph nodes than the standard procedure, aiming for better detection of cancer spread. The study compares outcomes between these two approaches, while considering surgery time and complication risks, which may be slightly higher with ePLND. During the study, participants will be monitored over a long-term period of up to 10 to 15 years. Researchers will measure prostate-specific antigen PSA persistence about 3 months after surgery and track biochemical recurrence-free survival within 24 months. Secondary measures include time to recurrence, metastasis, survival rates, complications, adverse events related to ePLND, and patient-reported outcomes. This comprehensive follow-up includes assessments during surgery, postoperatively, and over many years to evaluate the overall impact of the surgical approaches.

Age: 18Years +MALEPhase Not Applicable
15 locations
N

Actively Recruiting

Healthy Volunteer

Chronic liver diseases, including non-alcoholic fatty liver disease, alcohol-related liver disease, viral hepatitis, and genetic or autoimmune liver diseases, present a growing global health challenge. These conditions can lead to progressive fibrosis and serious complications like cirrhosis and liver cancer. Researchers are investigating a new approach using 4D-MRI to develop a quantitative Liver Deformation Biomarker qLDB that could offer a non-invasive way to assess liver fibrosis and improve diagnosis. The study uses a novel 4D-MRI technique that captures detailed images of the liver and abdominal organs during natural breathing and heartbeats at a high frame rate. This allows measurement of the livers elastic deformation without harmful X-rays. Participants include patients with chronic or acute liver conditions and healthy volunteers, all assessed by 4D-MRI. The goal is to compare liver deformation patterns between these groups to identify new biomarkers for staging liver fibrosis. Participants will undergo MRI scans to measure changes in liver deformation over 90 days. Researchers will assess mechanical changes in the liver, compare 4D-MRI results to other imaging methods like ultrasound elastography and standard MRI, and evaluate the diagnostic accuracy. The study includes monitoring liver motion caused by breathing and cardiac pulsation. The entire process is designed to be safe and non-invasive, with no radiation exposure, and participants will be followed for key outcome measurements during this period.

Age: 18Years +All GendersPhase Not Applicable
2 locations
S

Actively Recruiting

Triple-negative breast cancer TNBC is a particularly aggressive form of breast cancer with higher relapse and mortality rates compared to other types. Achieving a pathological complete response pCR in the tumor and affected lymph nodes is an important factor for better outcomes. This phase 2 trial evaluates whether the drug INT230-6 administered before surgery can increase the pCR rate in early TNBC patients and examines its tolerability and other outcomes such as breast-conserving surgery possibilities. Participants are randomized into two groups one receives a single injection of INT230-6 directly into the primary tumor followed by standard neoadjuvant immuno-chemotherapy and surgery, while the other receives no initial injection but starts the same immuno-chemotherapy and surgery regimen. The neoadjuvant therapy follows the Keynote-522 protocol including pembrolizumab combined with chemotherapy drugs given over approximately 24 weeks, followed by surgery and further assessments. During the study, participants undergo tumor assessments by MRI and pathological evaluation after surgery to measure the pCR in breast and lymph nodes. Researchers monitor safety, treatment response, event-free survival, and breast conservation rates, with evaluations occurring up to about 30 weeks post-treatment start. The trial is conducted under the oversight of the Swiss Cancer Institute and includes regular clinical visits, imaging, laboratory tests, and questionnaires to assess outcomes and tolerability over the study period.

Age: 18Years +All GendersPhase 2
10 locations

1-10 of 25

1